Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
41
RARE Quote, Financials, Valuation and Earnings
Last price:
$35.06
Seasonality move
:
11.76%
Day range:
$38.54 - $39.42
52-week range:
$29.59 - $60.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.28x
P/B ratio:
14.08x
Volume:
588.3K
Avg. volume:
940.8K
1-year change:
-9.08%
Market cap:
$3.6B
Revenue:
$560.2M
EPS (TTM):
-$6.34
Analysts' Opinion
-
Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $91.80, Ultragenyx Pharmaceutical has an estimated upside of 136.17% from its current price of $38.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $39.00 representing 100% downside risk from its current price of $38.87.
Fair Value
-
According to the consensus of 13 analysts, Ultragenyx Pharmaceutical has 136.17% upside to fair value with a price target of $91.80 per share.
RARE vs. S&P 500
-
Over the past 5 trading days, Ultragenyx Pharmaceutical has overperformed the S&P 500 by 0.87% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ultragenyx Pharmaceutical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ultragenyx Pharmaceutical has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Ultragenyx Pharmaceutical reported revenues of $164.9M.
Earnings Growth
-
Ultragenyx Pharmaceutical has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ultragenyx Pharmaceutical reported earnings per share of -$1.39.
Enterprise value:
3B
EV / Invested capital:
--
Price / LTM sales:
6.28x
EV / EBIT:
--
EV / Revenue:
5.34x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.89x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$483.5M
Return On Assets:
-38.16%
Net Income Margin (TTM):
-101.6%
Return On Equity:
-194.36%
Return On Invested Capital:
-194.36%
Operating Margin:
-74.16%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $363.3M | $434.2M | $560.2M | $127.4M | $164.9M | |
| Gross Profit | $335M | $389M | $483.5M | $115.3M | $148M | |
| Operating Income | -$648.9M | -$569.2M | -$536M | -$122M | -$122.3M | |
| EBITDA | -$640.5M | -$516.5M | -$469M | -$101.3M | -$108.8M | |
| Diluted EPS | -$10.11 | -$8.33 | -$6.34 | -$1.52 | -$1.39 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $856.6M | $883.9M | $732.2M | $817.1M | |
| Total Assets | $1.8B | $1.5B | $1.5B | $1.5B | $1.5B | |
| Current Liabilities | $189.6M | $181.4M | $261.2M | $280.4M | $344.2M | |
| Total Liabilities | $605.2M | $599.8M | $1.2B | $1.2B | $1.2B | |
| Total Equity | $1.2B | $922.6M | $352.5M | $275.4M | $262.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$380.5M | -$474.8M | -$414.2M | -$83.9M | -$79.5M | |
| Cash From Investing | -$291.7M | $168M | -$17.8M | -$107M | $102.7M | |
| Cash From Financing | $501.2M | $388.1M | $399.2M | $330.6M | $3.2M | |
| Free Cash Flow | -$526.6M | -$521.6M | -$434.2M | -$85.5M | -$80.2M | |
RARE
Sector
Market Cap
$3.6B
$35.1M
Price % of 52-Week High
64.39%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-9.08%
-40.62%
Beta (5-Year)
0.337
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$38.49
200-day SMA
Sell
Level
$46.38
Bollinger Bands (100)
Sell
Level
36.98 - 44.86
Chaikin Money Flow
Buy
Level
27.9M
20-day SMA
Buy
Level
$36.09
Relative Strength Index (RSI14)
Buy
Level
59.13
ADX Line
Buy
Level
24.36
Williams %R
Neutral
Level
-21.3581
50-day SMA
Buy
Level
$37.95
MACD (12, 26)
Buy
Level
0.51
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
26.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.161)
Sell
CA Score
(Annual)
Level (-3.3197)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (3.7644)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Stock Forecast FAQ
In the current month, RARE has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RARE average analyst price target in the past 3 months is $91.80.
-
Where Will Ultragenyx Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ultragenyx Pharmaceutical share price will rise to $91.80 per share over the next 12 months.
-
What Do Analysts Say About Ultragenyx Pharmaceutical?
Analysts are divided on their view about Ultragenyx Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ultragenyx Pharmaceutical is a Sell and believe this share price will drop from its current level to $39.00.
-
What Is Ultragenyx Pharmaceutical's Price Target?
The price target for Ultragenyx Pharmaceutical over the next 1-year time period is forecast to be $91.80 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RARE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ultragenyx Pharmaceutical is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RARE?
You can purchase shares of Ultragenyx Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ultragenyx Pharmaceutical shares.
-
What Is The Ultragenyx Pharmaceutical Share Price Today?
Ultragenyx Pharmaceutical was last trading at $35.06 per share. This represents the most recent stock quote for Ultragenyx Pharmaceutical. Yesterday, Ultragenyx Pharmaceutical closed at $38.87 per share.
-
How To Buy Ultragenyx Pharmaceutical Stock Online?
In order to purchase Ultragenyx Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.07% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 11% over the past day.
